Revelation Biosciences completes enrollment in Gemini study

Revelation Biosciences announced that it has completed enrollment and dosing of its first in human Phase 1 clinical study. The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy individuals 18 to 55 years of age. The forthcoming top-line data will include primary end points of safety and tolerability along with exploratory endpoints including multiple biomarkers of activity to demonstrate stimulation of the innate immune response. If positive, the data from this Phase 1 clinical study will support future program development of Gemini across multiple indications.